RT Journal Article SR Electronic T1 In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.09.21263319 DO 10.1101/2021.09.09.21263319 A1 Creemers, Jeroen A1 Ankan, Ankur A1 Roes, Kit C.B. A1 Schröder, Gijs A1 Mehra, Niven A1 Figdor, Carl G. A1 de Vries, I. Jolanda M. A1 Textor, Johannes YR 2023 UL http://medrxiv.org/content/early/2023/01/30/2021.09.09.21263319.abstract AB Late-stage cancer immunotherapy trials often lead to unusual survival curve shapes, like delayed curve separation or a plateauing curve in the treatment arm. It is critical for trial success to anticipate such effects in advance and adjust the design accordingly. Here, we use in silico cancer immunotherapy trials – simulated trials based on three different mathematical models – to assemble virtual patient cohorts undergoing late-stage immunotherapy, chemotherapy, or combination therapies. We find that all three simulation models predict the distinctive survival curve shapes commonly associated with immunotherapies. Considering four aspects of clinical trial design – sample size, endpoint, randomization rate, and interim analyses – we demonstrate how, by simulating various possible scenarios, the robustness of trial design choices can be scrutinized, and possible pitfalls can be identified in advance. We provide readily usable, web-based implementations of our three trial simulation models to facilitate their use by biomedical researchers, doctors, and trialists.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJC was funded by the Radboudumc. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT and AA were supported by a Young Investigator Grant (10620) from the Dutch Cancer Society. JT and GS were also supported by NWO grant VI.Vidi.192.084.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code is available at GitHub: https://github.com/jeroencreemers/in-silico-clinical-trials https://github.com/jtextor/insilico-trials ICIimmune checkpoint inhibitorNCCTGNorth Central Cancer Treatment GroupODEordinary differential equationOSoverall survivalPHAproportional hazard assumption